With the increasing prevalence of obesity, the interest of research in nonalcoholic fatty pancreas disease (NAFPD) has grown. Even though the pancreas appears more susceptible to lipid accumulation compared with the liver, NAFPD has been less investigated due to the limits in detecting techniques. Several definitions and synonyms for NAFPD are used by authors and can be misleading. This, together with differences in methodology and ethnicity, make the integration and comparison of studies on this topic challenging. NAFPD could be used as an early indicator of ectopic fat deposition, which is recognized as a key factor of obesity cardio-metabolic complications. However, evidence that NAFPD has a pathogenetic role in type 2 diabetes is also emerging. This article reviews the current state of knowledge on the clinical and pathophysiologic relevance of NAFPD in β-cell function and insulin resistance.
| INTRODUCTION
The global epidemic of obesity may largely explain the concurrent increase in the incidence and prevalence of type 2 diabetes (T2DM) over the last decades.
Therefore, the study of adipose tissue biology has gained an enormous research interest. This has gradually transformed adipose tissue from an inert lipid store into a metabolically dynamic endocrine organ capable of synthesizing biologically active compounds involved in metabolic homeostasis, as well as in many biological functions. [1] [2] [3] Although the epidemiological association between obesity and T2DM in general is well described, 4 the evidence of pathophysiological connection between them has been fully appreciated only in recent years. This issue has raised even more attention because of accumulating evidence that also a modest weight loss, induced by dietary interventions, 5, 6 physical exercise, 7, 8 and drugs and bariatric surgery procedures, 9,10 is capable of significantly reducing T2DM risk and improving glycemic control.
| THE CAUSAL LINK BETWEEN OBESITY AND TYPE DIABETES
Genome-wide association scans (GWAS) and candidate gene approaches have so far identified ∼40 genes associated with T2DM
and a similar number, but different, with obesity. 11, 12 Most of T2DM genes appear related to β-cell dysfunction, with many fewer involved in pathways related to insulin resistance independent of adiposity. 13 However, the identified genes are estimated to predict only 15% of T2DM. 14 This low predictive power may reflect the importance of environmental factors and epigenetic or gene-environment interactions that are not detected by population genetics-based methods.
Chronic positive energy balance, by promoting deposition of triglycerides and intermediates of lipid metabolism such as diacylglycerol and Acyl-CoA in adipose and non adipose tissues, triggers harmful cellular responses including activation of inflammatory signalling pathways, mitochondrial dysfunction, and endoplasmic reticulum and oxidative stresses. 15 This cascade of lipotoxic damage in adipose tissue recruits and activates immune cells, mainly represented by macrophages, which further increase local inflammation 16 and orchestrate the detrimental adaptive responses of adipose tissue. 17 These responses, collectively with those taking place in the liver and skeletal muscle, the classical target organs of insulin, contribute to the pathogenesis of insulin resistance which is the key element of obesityrelated metabolic derangements.
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Initially, insulin resistance can be overcome by an increased insulin production by the pancreas, resulting in hyperinsulinemia. Afterwards, during the progression towards overt T2DM, β-cell failure to compensate adequately the greater insulin requirements occurs. [18] [19] [20] The common dysfunctional β-cell phenotype in T2DM is characterized by diminished glucose sensing, increased basal insulin secretion, blunted first-phase insulin secretory response to glucose, and increased proinsulin:insulin ratios 21, 22 together with a presumed decrease in insulin production. 21 Having said that β-cell dysfunction could be primarily due to genetic or epigenetic predisposing factors, whether this decompensation is part of the obesity-induced metabolic derangements or secondary to hyper-functioning β-cells is unclear. 21, 23, 24 The influence of obesity on T2DM risk is determined not only by the degree of obesity but also by distribution of fat mass. Indeed, whereas abdominal obesity confers an increased risk for T2DM, metabolic syndrome and cardiovascular disease, 25 preferential fat accumulation in gluteo-femoral region confers a lower risk and, as learned from lipodystrophies, may be even protective. 26, 27 In addition, there are numerous ectopic fat depots that may serve specialized functions related to their neighbouring tissues, [28] [29] [30] [31] playing an emerging local pathophysiological role in obesity complications.
| ECTOPIC LIPIDS
As previously mentioned, when obesity develops and the circulating lipids exceed storage and metabolic capacity of adipose tissue, a progressive and abnormal retention of lipids within non-adipose tissues occurs. This process, termed "steatosis", 32 may involve liver, heart, skeletal muscle and pancreas. 33 Lipid droplets accumulate in the cytoplasm of cells, thus leading to cell dysfunction or death, a phenomenon called lipotoxicity. 34 In human studies, intrahepatic and intramyocellular lipid content emerged as much stronger predictors of insulin resistance than circulating fatty acids, suggesting that intracellular lipids may impair insulin signalling and therefore cause insulin resistance. 35 Similarly, accumulation of fat in the heart has been associated with cardiac dysfunction and heart failure, 36 possibly contributing to diabetic cardiomyopathy development. 37 Lipid accumulation can occur by increased uptake of FFAs, increased synthesis within the tissue involved, or reduced FFAs oxidation/disposal, although the relative contribution of these factors may vary in different physiological states and tissues. 38 
| NONALCOHOLIC FATTY PANCREAS DISEASE
Ogilvie coined the term "pancreatic lipomatosis" to describe the excessive storage of fat in pancreatic tissue in his human post mortem study.
Thereafter, owing to the lack of distinction between the lipid accumulation within acinar and β-cells and intra-pancreatic adipocyte infiltration, the accumulation of fat in the pancreatic gland has been referred to using various synonyms, including pancreatic lipomatosis, pancreatic steatosis, fatty replacement, fatty infiltration, fatty pancreas, lipomatous pseudohypertrophy, and nonalcoholic fatty pancreas disease (NAFPD). 39 Because pancreatic steatosis also occurs in nonobese individuals (that is, patients with cystic fibrosis, iron overload, viral infections, chemotherapy, and chronic alcohol abuse), 39, 40 Smits and van Geenen proposed that the term "NAFPD" should be reserved for pancreatic steatosis associated with obesity and metabolic syndrome, 40 condition possibly reversed by weight reduction or appropriate medications. 41, 42 On the other hand, the term "fatty replacement" should be used for those conditions that lead to acinar cell death and irreversible replacement by adipocytes. 40, 43 From an epidemiologic perspective, few studies aimed to estimate the prevalence of NAFPD, which ranges from 16% and 35% in Asian populations. [44] [45] [46] However, owing to the lack of clear definitions as well as of standard diagnostic tools, the prevalence of NAFPD in general population is so far unknown. 47 
| Histology and imaging techniques
Intracellular lipid accumulation can be demonstrated in exocrine parenchyma and islet cells by immunohistochemistry or electron microscopy. 48, 49 However, because the histological examination needs biopsy and can be also hampered by grading errors due to the irregular accumulation of pancreatic fat, 50 pancreatic steatosis is most commonly diagnosed by means of imaging techniques.
Pancreatic steatosis presents as hyperechogenic at ultrasonography, but especially in obese patients, the pancreas is not always easily visible with this technique. In addition, pancreatic fibrosis has similar ultrasonographic features, which preclude the routine use of ultrasonography as a screening tool for lipid deposition in the pancreas. 51 Computed tomography (CT) with or without contrast can also be used. The density of steatotic pancreas is similar to adipose tissue on CT scan, and the amount of pancreatic fat can be measured using Hounsfield units, correlated to the spleen, although no cutoff points have been defined yet. 52 Several magnetic resonance imaging (MRI) methods have been proposed to measure lipids in the pancreas, such as phase-opposed phase, Dixon method, the spectral-spatial excitation techniques, 53, 54 and, more recently, the 3-dimensional fat-water MRI method. 55 However, proton magnetic resonance spectroscopy (1H-MRS) is the current gold standard for noninvasive quantification of pancreatic triacylglycerol content, being almost equivalent to histology and biochemical measurements for in vivo use. 56 However, MRI and 1H-MRS still have some limitations, including high cost, long scanning time, and susceptibility to magnetic resonance chemical shift artefact due to the surrounding visceral fat. 57 In addition, sensitivity and specificity for the detection of pancreatic steatosis with these imaging techniques have not been determined yet.
| Pathophysiology
Animal model studies have shown that maternal obesity throughout pregnancy and lactation can induce a significant increase in markers indicative of a NAFPD phenotype, 58 which only become evident when offspring are subsequently challenged by a post-weaning obesogenic diet, suggesting a priming effect of maternal obesity. 59 In human studies, pancreatic fat content has been closely associated with increasing BMI, insulin resistance, metabolic syndrome, and hepatic fat content. 44 Whereas NAFPD frequently coexists with NAFLD, 60 the association between NAFPD and visceral adiposity has been found in some 61, 62 but not all 63 studies. The relationship between pancreatic fat content and visceral fat seems influenced by ethnicity, resulting stronger in Hispanics than African Americans.
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Of note, the pancreas seems to be more susceptible to fat deposition compared with the liver. In fact, 15 weeks of high-fat diet determined a 5-fold greater fat accumulation in pancreas compared with the liver in mice, 48 and accordingly, in human obesity, the proportion of fat was found to be higher in the pancreas than in skeletal muscle and liver. 54 Also, increasing age has been associated with pancreatic steatosis.
Saisho et al have found that pancreatic fat content linearly increased with age throughout childhood and reached a plateau until the age of 50 years. 64 In multiple regression analyses, the variance of pancreas lipid content explained by gender and visceral adipose tissue measured with MRI was 59.2%. 62 In addition, men have a higher pancreatic fat content compared with BMI-matched women 62 and the highest prevalence of NAFPD at the age of 40 to 49 years, while the prevalence of NAFPD in women was very low until menopause. 65 This suggests that aging and hormonal changes have relevance to the development of NAFPD, although confirmatory studies are needed.
The accumulation of triglycerides may occur in pancreatic parenchymal tissue 63 with an almost identical distribution in the exocrine and endocrine pancreas 66 or in adipocytes, 67 so that 1H-MRS measurements of lipids in the whole pancreas have been proposed as a surrogate marker for islet lipids. 66 Nevertheless, the intracellular lipid accumulation has been described to precede the adipocyte infiltration. 66 On the other hand, according to other authors, fat deposition in the human pancreas appears to occur mainly in interlobular septa, rather than in cells. 68, 69 Whether leukocyte infiltration accompanies pancreatic steatosis is also still controversial. 43, 60 The potential sources of lipids accumulating in the pancreas may be represented by circulating FFAs, de novo lipogenesis, and dietary fat intakes. Phospholipids turnover could also provide a source of extracellular FFAs.
| NAFPD AND TYPE 2 DIABETES
Some cross-sectional studies have shown that subjects with T2DM
have an increased MRS-measured or MRI-measured pancreatic fat content compared with non-diabetics 63, 70, 71 and that, in turn, subjects with NAFPD a higher proportion of T2DM than non-NAFPD group. 44 In addition, NAFPD has been found associated with T2DM independent of adiposity and other cardiometabolic risk factors, 72 suggesting that NAFPD might represent an additional factor other than NAFLD able to deteriorate glucose metabolism (Figure 1 ).
By contrast, others observed no difference in pancreatic fat measured by histology at autopsy or CT scans 64 in relation to the presence of T2DM.
However, most studies were cross-sectional. To our best knowledge, the so far only one 5-year retrospective cohort study examining the longitudinal effects of pancreatic steatosis on incident T2DM in Japanese population. In this study, the association between pancreatic steatosis and increased incidence of T2DM disappeared after adjustment for potential confounders including BMI and liver attenuation, 73 even if it remains to be elucidated whether these findings could be observed in longer follow-up and in other ethnic groups.
| NAFPD and insulin resistance
Obesity represents a common pathway for the development of NAFPD, NAFLD, and T2DM.
Concurrence of fatty pancreas and fatty liver at ultrasonography was found in 67.9% of subjects, with a negative predictive value of NAFLD in normal pancreas of 96.4%. 74 Even in obese paediatric population, approximately 50% of patients with NAFLD and 80% of biopsy-proven nonalcoholic steatohepatitis concurrently had NAFPD. 75 The positive correlation of NAFLD and fatty pancreas was also demonstrated in autopsy 60 or 1H-MRS studies. 76 In addition, subjects with fatty pancreas presented a more advanced form of liver
Pathophysiology and clinical consequences of nonalcoholic fatty pancreas disease, term reserved to accumulation of pancreatic fat owing to obesity and metabolic syndrome. Abbreviation: NAFPD, nonalcoholic fatty pancreas disease disease (reflected by higher values of fibrosis, ballooning and NAFLD Activity Score) compared with the group without NAFPD. 75 The homeostasis model assessment-(HOMA-IR) and euglycemic clamp-based estimates of insulin resistance were found positively correlated with the severity of NAFPD 74, 77 in patients with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT), whereas few others did not confirm these relationships in obese individuals. 61, 62 Similarly, whether the association between NAFPD and insulin resistance and glucose metabolism is independent of obesity and nonalcoholic fatty liver disease is still debated. However, whereas in a community cohort study the pancreatic fat content remained significantly associated with HOMA-IR even after adjusting for liver fat and BMI, 65 in a multivariate logistic regression analysis, this association disappeared after further adjustment for visceral fat, 74 suggesting that the latter, rather than overall adiposity or pancreatic fat, does mediate the association between NAFPD and insulin resistance. In this light, NAFPD would be just part of a cluster of abnormalities during the course of obesity.
| NAFPD and β-cell dysfunction
Several in vitro and animal studies have indicated that fatty infiltration of the pancreas contributes to a loss of β-cell mass and function. 78, 79 In rats, chronic exposure to high-fat diet was capable of inducing an acute inflammatory response and both acinar and islets cells damage by increasing pancreatic FFAs content. 80 Accordingly, in obese Zucker prediabetic rats, the triacylglycerol content of islets preceded the development of T2DM.
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In human studies, pancreatic steatosis appears to be present and the amount of pancreatic fat an even stronger determinant of OGTT-, but not hyperglycemic clamp-, 77 due to more heterogeneous stages in the progression of β-cell failure in young compared with older adults. 63 In fact, in children with a rare mutation in carboxyl-ester lipase, pancreatic steatosis reflects early events in the pathogenesis of diabetes.
Although, as said, many authors have emphasized an upward trend in pancreatic fat content during the progression of diabetic state, 81, 82 the majority of the studies could not demonstrate associations between NAFPD and overt T2DM. 63, 64 In line with this, no relationship between pancreatic fat and the first phase insulin response to oral glucose challenge was found regardless of glucose tolerance status. 83 Therefore, on the basis of current evidence, several authors conclude that pancreatic steatosis is probably not a cause of lipotoxicity in pancreatic β-cells, but merely a marker of β-cell dysfunction. 33, 40, 84 In this context, as explanation for the lack of association between pancreatic fat and β-cell dysfunction in diabetic patients, it has been theorized that once T2DM occurs, other factors superimposing the effect of pancreatic steatosis may rather account for the progressive decline in β-cell function. 63 Namely, owing to many deleterious cascades, including oxidative stress, inflammation, apoptosis, and islets hypoperfusion, deterioration of β-cell functioning may develop at a rate disproportional to that of pancreatic fat accumulation. 63 Instead, in prediabetes, lipid metabolites and adipocyte secretory products, 85 whose concentration is likely high in the proximity of the islets, could contribute more blatantly to the progression of β-cell dysfunction ( Figure 2 ).
Regardless of the causality issue, in the effort to find an explanation for the higher pancreatic fat content observed in diabetics relative to nondiabetics, it has been postulated that, once diabetes develops, fatty replacement of damaged tissue may contribute to the extra-islet pancreatic fat deposition. 63 Alternatively, the increased levels of 
| OTHER POTENTIAL CLINICAL CONSEQUENCES OF NAFPD
As suggested by prospective observational studies investigating the association between obesity and pancreatic cancer, 87 NAFPD may promote pancreatic cancer via steatopancreatitis (NASP) and pancreatic fibrosis, a concept analogous to nonalcoholic fatty liver disease which can cause hepatic cancer via steatohepatitis and hepatic cirrhosis. 88 The observation that fat mass is markedly greater in pancreatic tumours of obese mice than in lean mice supports this hypothesis.
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FIGURE 2 It has been theorized that once T2DM occurs, the activation of many deleterious cascades superimposing the effect of pancreatic NAFPD mostly account for the progressive decline in β-cell function, which, indeed, because then appears to develop at a rate disproportional to that of pancreatic fat accumulation. Abbreviation: NAFPD, nonalcoholic fatty pancreas disease However, whether pancreatic fibrosis, which can give rise to pancreatic cancer, is primarily caused by NASP or whether pancreatic cancer causes fibrosis owing to duct obstruction is unknown.
Nevertheless, in patients with pancreatic cancer, pancreatic steatosis appears to facilitate its dissemination and increases the lethality of the disease. 67 Fatty pancreas may also exacerbate the severity of acute pancreatitis, 40 in line with the notion that obesity is associated with developing organ failure, 90 local complications, 91 and increased mortality in patients with pancreatitis. 92 This may occur possibly through the secretion of toxic fats and adipocitokines by pancreatic adipocytes, which create an inflammatory milieu in the pancreas, making this organ more susceptible to pancreatitis. 93 Finally, pancreatic steatosis is also a risk factor for the development of pancreatic fistula after pancreatic surgery 94, 95 but has been
shown together with obesity itself to increase the yield of pancreatic islet isolation for transplantation 96, 97 ( Figure 1 ).
| CONCLUSIONS
With the dramatic world-wide increase in obesity prevalence, NAFPD has become object of a growing research interest. However, whereas according to in vitro and animal findings NAFPD may directly contribute to β-cell dysfunction in T2DM, current evidence in human studies remains inconclusive. As summarized by Catanzaro R et al, the 3 major hypotheses about NAFPD that are still to be proven, or indeed refuted, by further research are: (1) the increased amount of lipids within pancreatic β-cells can cause their dysfunction possibly through a mechanism of lipotoxicity, at least in subjects with an already impaired glucose metabolism; (2) intrapancreatic adipocytes may exert a negative paracrine effect on β-cells; and (3) NAFPD and T2DM are just both obesity consequences. 98 Because contradictory findings about the relationship between NAFPD and β-cell dysfunction may possibly arise from different methods for assessing pancreatic fat content and β-cell function, as FIGURE 3 Putative interplay between nonalcoholic fatty pancreas disease and insulin resistance and β-cell dysfunction. During long-term positive energy balance, dietary fatty acids and hyperinsulinemia stimulate hepatic steatosis (NAFLD), leading to increased production and secretion of very-low-density lipoprotein (VLDL), which will increase free fatty acid (FFAs) delivery to pancreatic islets. Insulin resistance also enhances FFAs release from adipose tissue, further increasing circulating FFAs. In β-cells, chronic exposure to elevated FFAs results in increased intracellular triacylglycerol content, decreased insulin gene expression, and blunted glucose-stimulated insulin secretion. In addition, hyperglycemia inhibits carnitinine-palmitoyl transferase-1 (CPT-1) via increasing malonyl coenzyme A (malonyl CoA), thus decreasing mitochondria β-oxidation and further promoting intracellular triglyceride (TG) accumulation. This, together with adipocyte-derived inflammatory adipocitokines, contributes to β-cell destruction, further blunting insulin secretion. Abbreviations: CPT-1, carnitinine-palmitoyl transferase-1; DG, diglycerides; FFAs, free fatty acids; PA, phosphatidic acid; TCA, tricarboxylic acid; TG, triglycerides; VLDL, very-low-density lipoprotein. Modified from Yu and Wang 47 well as from differences in age, ethnicity, and individual liposusceptibility thresholds, additional longitudinal research is warranted to validate the role NAFPD in the development of T2DM and, hence, to unravel the underlying pathophysiology.
CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.
ORCID
Valeria Guglielmi http://orcid.org/0000-0002-6912-7814
Paolo Sbraccia http://orcid.org/0000-0001-9634-1501
